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OBJECTIVE— To examine the effect of intravenous iron and erythropoietin-stimulating
agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease
(CKD).
RESEARCHDESIGNANDMETHODS— This was a prospective study of patients with
type 2 diabetes and CKD stage IIIB or IV undergoing intravenous iron (group A) and/or ESA
(group B). Full blood profiles were determined over the study period. Glycemic control was
monitored using A1C, seven-point daily glucose three times weekly, and continuous glucose
monitoring (CGM).
RESULTS— There were 15 patients in both group A and group B. Mean A1C (95% CI) values
fell in both groups (7.40% [6.60–8.19] to 6.96% [6.27–7.25], P 0.01, with intravenous iron
and 7.31% [6.42–8.54] to 6.63% [6.03–7.36], P 0.013, ESA). There was no change in mean
blood glucose in group A (9.55 mmol/l [8.20–10.90] vs. 9.71 mmol/l [8.29–11.13], P 0.07)
and in group B (8.72 mmol/l [7.31–10.12] vs. 8.78 mmol/l [7.47–9.99], P 0.61) over the study
period. Hemoglobin and hematocrit values significantly increased following both treatments.
There was no linear relationship found between the change in A1C values and the rise of
hemoglobin following either treatment.
CONCLUSIONS— Both iron and ESA cause a significant fall in A1C values without a
change to glycemic control in patients with diabetes and CKD. At the present time, regular
capillary glucose measurements and the concurrent use of CGM remain the best alternative
measurements of glycemic control in this patient group.
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A1C is the most widely accepted andused method of assessing chronicglycemia in patients with diabetes.
It is formed by the irreversible binding of
glucose to hemoglobin over the lifespan
of the erythrocyte (1,2).
Patients with chronic kidney disease
(CKD) are commonly anemic due to a va-
riety of reasons, including functional or
absolute iron deficiency and erythropoie-
tin insufficiency (3,4). Treatment of ane-
mia in patients with CKD using iron
replacement therapy and erythropoietin-
stimulating agents (ESAs) has resulted in
significant improvements to quality of life
and the correction of anemia without the
need for blood transfusions (3–5).
There are several studies (6–9) that
show a fall of A1C in patients treated with
ESA and iron therapy. These studies are
mostly in patients already receiving he-
modialysis and those without diabetes.
The effect of the lowering of the A1C val-
ues following either treatment has been
postulated to be secondary to the forma-
tion of new erythrocytes in the blood
stream, causing a change of proportion of
young to old cells, and also from an alter-
ation in the red-cell glycation rates
(10,11).
Despite this, a comprehensive analy-
sis of the relationship between glycemic
control and A1C changes in patients un-
dergoing both iron and ESA therapy has
never been performed using robust meth-
ods, such as seven-point daily capillary
glucose monitoring (7PGM) or using
CGM devices. Thus, any class effect that
iron therapy and ESA may have on A1C
values could in fact represent a parallel
change to glycemic control along with the
currently postulated physiological
changes. Furthermore, the effect of the
fall in A1C following these two therapies
has not been well studied in patients not
already on hemodialysis.
This study therefore sought to estab-
lish how intravenous iron and ESA ther-
apy influence A1C values in patients with
type 2 diabetes and CKD not on hemodi-
alysis. Robust monitoring of blood glu-
cose was performed throughout the study
period to determine if the anticipated fall
in A1C was a true reflection of glycemic
control.
RESEARCH DESIGN AND
METHODS— This was a prospective
study of patients with type 2 diabetes and
CKD stage IIIB or IV (estimated glomeru-
lar filtration rate [Modification of Diet in
Renal Disease] 15–44 ml/min per 1.73
m2) selected for treatment with intrave-
nous iron and/or ESAs between January
2009 and December 2009 inclusive. All
patients were attending a single renal ser-
vice where the decision to commence iron
and ESA therapy was made by the attend-
ing physician.
The study consisted of two groups.
The first group (group A) were patients
selected for iron therapy according to
clinical need, and the second group
(group B) consisted of patients who were
those needing ESA treatment. Glycemic
control in both patient groups was as-
sessed in the month leading up to treat-
ment and once again for a 4-week period
4 months after therapy. These assess-
ments comprised the measurement of
A1C, seven-point glucose day profiling
(7PGM) three times weekly, and CGM for
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a minimum of 48 h. A more detailed ac-
count of the study methodology and pa-
tients are described below.
Patient selection and exclusion
criteria
Iron therapy group (group A). All pa-
tients selected for iron therapy had either
absolute or functional iron deficiency as
evidenced by serum ferritin values 200
g/l. All patients had hemoglobin 10.5
g/dl. Patients in this group were not on
previous or concurrent ESA therapy and
were vitamin B12 and folate replete. In-
travenous iron was given as a single dose
in the form of low–molecular weight iron
dextran (Cosmofer) dependent on the pa-
tient’s body weight. This was delivered as
an initial intravenous test infusion of 100
mg of iron over 1 h followed by the re-
maining dose over the next 2–4 h.
ESA therapy group (group B). All pa-
tients receiving ESA therapy had hemo-
globin 10.5 g/dl and were considered
iron, vitamin B12, and folate replete prior
to initiation. Patients were considered
iron replete following a serum ferritin
value200g/l or having received intra-
venous iron at least 6 weeks prior to ESA
therapy. ESA treatment was given in the
form of darbepoetin  at 750 nano
grams/kg fortnightly and continued
throughout the period of the study. The
dose of ESA was titrated monthly to
achieve a target hemoglobin 10.5–12
g/dl.
Exclusion criterion
Patients with known hemoglobinopathy,
with a history of transfusion or bleeding
with the last 6 months, who had been pre-
viously treated with ESA on renal replace-
ment, or with previous transplantation
were excluded from the study.
Sample analysis and monitoring of
glycemic control
Patients in groups A and B were provided
with the Abbott Freestyle Freedom Lite
glucose sensor (Abbott Diagnostics,
Maidenhead, U.K.). Patients were re-
quested to perform 7PGM three times
weekly 1 month before commencement
of treatment until the end of the study.
7PGM was defined as premeal, 90-min
postmeal, and prebedtime capillary glu-
cose measurements.
CGM was performed using the
Medtronic CGMS Ipro Continuous Glu-
cose Recorder (Medtronic Minimed,
Northridge, CA). Using this system, mea-
surements of interstitial glucose levels
were made 228 times over a 24-h period.
Callibration of CGM readings were made
based on patient 7PGM over the similar
time period. All patients had CGM per-
formed for 2–4 days. This was done prior
to ESA and iron therapy and once again at
the end of the study.
Results from the 7PGM and CGM
were downloaded from their respective
meters for data analysis. Results from the
CGM included at least a successful 24-h
profile over the monitoring period with
no gaps 120 mins. The management of
diabetes control was left to the patients
and their health care professional. Treat-
ment for glycemic control was monitored
throughout the study period.
Blood was drawn fasting from all pa-
tients for A1C and full blood profile. All
A1C measurements were made using ion-
exchange chromatography via the Mena-
rini HA-8160 A1C analyser (A. Menarini,
Berkshire, U.K.). It has been shown that
there is no interference between carbamy-
lated hemoglobin (present in uremia) and
A1C using this analyser (12). Patients in
groups A and B had samples taken 1
month before commencement of therapy
and once again 4 months following treat-
ment initiation.
Data analysis
All data were tabulated using Microsoft Ex-
cel and statistical analysis was made using
SPSS 16.0 using paired t tests where
appropriate.
Mean blood glucose (MBG) pre- and
posttreatment was calculated by taking
the average of the daily mean glucose val-
ues where there were three more capillary
glucose readings per day. As glucose val-
ues were measured more frequently over
CGM periods, the results were weighted
to ensure each measurement was propor-
tional to the inverse of the total number of
measurements taken the same day similar
to that done in the A1C-Derived Average
Glucose Study (13).
Power calculation
Data from previous studies were used to
calculate the statistical power required in
the knowledge that iron has previously
been shown to have a larger effect on A1C
than ESAs (6,14). Assuming the intra-
subject variation of A1C is Gaussian (15),
nine patients were required to detect a 1.2%
fall in A1C in group A and 13 patients to
detect a 1.0% fall in group B, with 80%
power to an  of P  0.05 using nQuery
(Statistical Solutions, Cork, Ireland). Ethical
approval was obtained from the local ethics
committee prior to the commencement of
the study (local research ethics committee
[LREC] no. 08/H1304/114).
RESULTS
Patient data
Intravenous iron therapy (group A).
Fifteen patients (9 male, six female, all
Caucasian, median age 72 years [inter-
quartile range {IQR} 68–74], median al-
bumin-to-creatinine ratio 6.3 [4.3–76.3])
agreed to participated in this arm of the
study. Six patients were diet controlled,
and nine patients were insulin requiring.
The follow-up period was (means  SD)
16.4  3.7 weeks.
ESA therapy (group B). Fifteen patients
(11 male, four female, all Caucasian, me-
dian age 70 years [IQR 62–75], median al-
bumin-to-creatinine ratio 9.3 [IQR 6.0–
93.4]) were recruited in this group. Four
patients were diet controlled, four were on
oral hypoglycemic agents, and seven were
insulin requiring. The follow-up time in this
group was 17.3  3.3 weeks. No patients
received additional oral or intravenous iron
therapy over the period of the study follow-
ing the initiation of ESA treatment.
Glucose measurements and control
No new treatments affecting glycemic
control (e.g., oral hypoglycemic agents,
steroids, ß-blockers) were initiated or al-
tered over the study period in all patients.
The CGM and the 7PGM data in-
cluded 1,300 and 250 measurements
per subject, respectively, for a total of
1,500 glucose tests over the entire study
period. Using the 7PGM results, there are
a mean 4.7 readings a day, of which 31%
of the seven-point profiles were complete.
The median days of CGM were 6. The
results of the CGM were retrospectively
calibrated with the 7PGM readings per-
formed over the similar period. MBG in
both groups did not change over the
study period. The results of these are
summarized in Tables 1 and 2.
A1C values
Despite a lack of change of glycemic con-
trol in the both groups, A1C concentra-
tions fell significantly (P  0.001 and
0.013, respectively, for groups A and B).
There was no linear relationship between
the change in A1C and hemoglobin con-
centration values. (group A, Pearson two
tailed, R2  0.329, P  0.23; group B,
R2  0.313, P  0.25).
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Subgroup analysis of group B
In the group of patients receiving ESA ther-
apy, there were seven patients (5 male, two
female, median age 72 years [IQR 62–79])
who received ESA therapy after iron treat-
ment and eight patients (six male and two
female, median age 69 years [61–74]) who
received ESA only. All patients who also re-
ceived iron were treated at least 6 weeks
prior to ESA therapy initiation.
There appeared to be a nonsignificant
trend toward ESA leading to a further de-
crease in A1C following the initial fall due
to iron (mean A1C 7.3–6.9%, P  0.36
following iron and 6.9–6.7%, P  0.13
following ESA). In contrast, the group of
patients receiving ESA therapy without
iron had a significant fall in A1C from 7.3
to 6.5% (P  0.02).
MBG did not change in either group
(9.12 vs. 9.21 mmol/l,P0.47 for ESA and
iron vs. 8,21 vs. 8.26 mmol/l, P 0.71 for
ESA only), and there was a concurrent rise
to hemoglobin (9.6–11.76 g/dl, P  0.01
vs. 9.4–11.3 g/dl,P0.01) and hematocrit
(0.310–0.347, P 0.01 vs. 0.331–0.384)
values following therapy.
CONCLUSIONS— ESAs and intra-
venous iron are commonly used therapies
in the management of anemia in patients
with CKD. Patients with both diabetes
and CKD have a higher prevalence of se-
vere anemia compared with patients with
CKD alone (16 –18). Despite the in-
creased usage of ESA agents, recent find-
ings have shown that the correction of
anemia to levels of hemoglobin in excess
of 12.5 g/dl in patients with type 2 diabe-
tes using this therapy has not led to an
improvement in mortality but rather an
increased risk of stroke. This needs to be
interpreted carefully, as the two groups
received disproportionate amounts of in-
travenous iron. Indeed, in the placebo
group it was noted that there was in in-
crease in the hemoglobin levels with ESA
agents. Hence, best practice would sug-
gest that correction of functional and ab-
solute iron deficiency should be obtained
prior to commencement of ESA (19). This
is the first study to robustly show that iron
and ESA treatments result in a fall in A1C,
which is independent of glycemic
changes in patients with diabetes and
CKD stage IIIb and IV.
Discordantly high A1C values com-
pared with glucose readings have been re-
ported in previous studies and case
reports on nondiabetic patients with iron
deficiency (10,11,20,21) and in patients
with type 1 diabetes in childhood and
pregnancy (22). The correction of the iron
deficiency in all these patient groups has
lead to a fall in A1C values in these pa-
tients, though the monitoring of glycemic
control of patients has not been as robust
compared with our study (using methods
such as fasting plasma glucose or two pre-
meal readings a day).
Several studies have also shown a fall
in A1C concentrations following ESA
treatment in patients with diabetes under-
going hemodialysis (7,8). Other than a
single case report (23), there was scarce
data to support the class effect of this ther-
apy on patients not on hemodialysis.
Nakao et al. (7) reported a fall in A1C
in nondiabetic patients with CKD on he-
modialysis following ESA therapy. The
1.2% fall in their study was much larger
when compared with our results. A plau-
sible explanation is that in contrast to our
study, iron therapy was given concur-
rently, which has likely to have potenti-
ated the A1C-lowering effect reported. A
proportion of patients in our study had
both therapies, and though there was a
similar trend of combined lowering of
A1C in this group, this failed to reach sta-
tistical significance.
Good glycemic control in patients
with diabetes and CKD has been shown to
be associated with better survival rates
(24). Proper assessment of glycemic con-
trol is therefore vital if this is to be
achieved. The results of our study show
both statistically and clinically significant
falls in the A1C following iron and ESA
treatment (mean 0.4% following iron and
0.7% following ESA) in the absence of a
change in glycemic control.
From a practical view, the data from
this study highlights several issues to which
diabetes management can be improved in
patients with diabetes and CKD. It shows
that A1C can be unreliable and can fall fol-
lowing treatment with both iron and ESA
therapy. It is essential that health care pro-
fessionals are aware of the potential fluctu-
ations of A1C that can occur in this patient
group. Alternative methods for measuring
glycemic control such as capillary glucose
testing and CGM should be used, and ther-
apy should not be based on the A1C value
alone. This has particular significance when
considering national, international, or
health service glycemic targets, such as the
Quality and Outcome Framework in the
U.K., which almost exclusively uses A1C as
the sole index by which treatment success is
judged.
Glycated albumin has been suggested
as an alternative marker to represent gly-
cemic control, as it was noted to be similar
(in contrast to A1C, which was higher) in
patients with iron deficiency and pre-ESA
compared with patients posttherapy
(8,20). Though this may be true, further
study is still required and better correla-
tion between glycated albumin and glyce-
Table 1—Patients on iron therapy
Before iron mean
(95% CI)
After iron mean
(95% CI) P*
A1C (%) 7.40 (6.60–8.19) 6.96 (6.27–7.25) 0.001
Hb (g/dl) 9.71 (9.32–10.05) 10.46 (9.97–10.75) 0.001
Hct 0.302 (0.285–0.316) 0.334 (0.314–0.354) 0.007
Ferritin (g/l) 122 (67–176) 307 (211–403) 0.001
MBG (mmol/l) 9.55 (8.20–10.90) 9.71 (8.29–11.13) 0.071
Estimated glomerular filtration rate 34.0 (31.9–36.2) 32.8 (30.4–35.2) 0.137
*Paired t test.
Table 2—Patients on ESA
Before ESA mean
(95% CI)
After ESA mean
(95% CI) P*
A1C (%) 7.31 (6.42–8.54) 6.63 (6.03–7.36) 0.013
Hb (g/dl) 9.52 (9.18–9.86) 11.51 (11.15–11.85) 0.001
Hct 0.324 (0.296–0.350) 0.378 (0.341–0.398) 0.001
Ferritin (g/l) 344 (241–447) 332 (211–354) 0.37
MBG (mmol/l) 8.72 (7.31–10.12) 8.78 (7.47–9.99) 0.893
Estimated glomerular filtration rate 30.5 (28.6–33.4) 31.0 (27.3–33.8) 0.613
*Paired t test.
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mic control is still needed before this
measurement to be more widely used.
The strengths of this study lies in the
robust monitoring of glycemic control in
patients. 7PGM and CGMS were used in
all patients and glycemic control, treat-
ment, and A1C values were monitored
closely. However, this study is limited by
its relatively small numbers, and though it
managed to show that A1C values fell
both with iron and ESA, there were insuf-
ficient numbers to confirm whether the
combined effect of both therapies had an
added A1C-lowering effects compared
with a single agent given alone.
Intravenous iron and ESA are increas-
ingly common therapies used in the man-
agement of anemia in patients with CKD
and diabetes. The present study has been
able to confirm that reported changes in
A1C following these treatments are in-
deed independent of changes in glycemic
control; therefore, caution is warranted in
the interpretation of A1C and manage-
ment of glycemia when based on this
measurement alone. At a time when self-
monitoring of blood glucose is being dis-
couraged, especially in non–insulin-
treated patients (25), regular capillary
glucose measurements, and the concur-
rent use of CGM if available, seems essen-
tial in order to accurately assess glycemic
control in this group of patients.
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